Lacosamida Combix (Lacosamide)

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

• Partial‑onset seizures: Reduces seizure frequency as adjunct therapy.
• Focal epilepsy: Helps achieve better seizure control when added to other antiepileptic drugs.
• Adjunctive therapy in epilepsy: Provides additional seizure reduction for patients not fully controlled by monotherapy.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and decreasing hyper‑excitability. By selectively targeting the persistent sodium current, it limits repetitive neuronal firing that underlies seizure generation, without significantly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: Light‑headed sensation, especially after dose initiation.
• Headache: Mild to moderate intensity, often transient.
• Nausea: Gastrointestinal discomfort that may improve with continued use.
• Fatigue: Generalized tiredness or reduced energy levels.
• Diplopia: Blurred or double vision, usually dose‑related.
• Somnolence: Increased sleepiness, particularly when combined with other CNS depressants.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: Severe skin reaction requiring immediate medical attention.
• Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmias.
• Suicidal thoughts: Emergence of depressive symptoms or suicidal ideation.
• Severe skin reactions: Toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms.
• Hypersensitivity reactions: Anaphylaxis or severe allergic response.
• Cardiac rhythm disturbances: Bradycardia or atrioventricular block.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Assess renal function: Adjust dosing in patients with significant impairment.
• Monitor cardiac conduction: Obtain baseline ECG and repeat if symptoms arise.
• Avoid abrupt discontinuation: Taper dosage under medical supervision to prevent seizure rebound.
• Use caution in hepatic impairment: Monitor liver enzymes periodically.
• Discuss pregnancy and breastfeeding: Weigh potential risks against benefits with the prescriber.
• Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase lacosamide plasma concentrations.
• Carbamazepine (enzyme inducer): Can reduce lacosamide effectiveness.
• Co‑administration with other sodium channel blockers (e.g., phenytoin): Increases risk of central nervous system depression.

Moderate Interactions (Monitor Closely)

• Antihypertensives: Potential additive hypotensive effect.
• Multiple antiepileptic drugs: Monitor for cumulative side effects such as dizziness or somnolence.
• Oral contraceptives: May reduce contraceptive efficacy; consider alternative methods.